JBC Transcription and Nuclear Factor Monoclonals

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M800189200 on January 22, 2008

J. Biol. Chem., Vol. 283, Issue 18, 12595-12603, May 2, 2008
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
283/18/12595    most recent
M800189200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Hastie, C.
Right arrow Articles by Naaby-Hansen, S.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hastie, C.
Right arrow Articles by Naaby-Hansen, S.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Interferon-{gamma} Reduces Cell Surface Expression of Annexin 2 and Suppresses the Invasive Capacity of Prostate Cancer Cells*Formula

Claire Hastie{ddagger}, John R. Masters§, Stephen E. Moss, and Soren Naaby-Hansen||1

From the {ddagger}School of Pharmacy and Biomedical Science, University of Portsmouth, Portsmouth, Hampshire PO1 2UP, United Kingdom, §Prostate Cancer Research Centre, Royal Free and University College London Medical School, London W1W 7EJ, United Kingdom, Division of Cell Biology, Institute of Ophthalmology, University College London, London EC1V 9EL, United Kingdom, and the ||Department of Clinical Immunology, Aalborg Sygehus, Århus University Hospital, DK-9100 Aalborg, Denmark

The effect of interferon-{gamma} (IFN{gamma}) treatment on cell surface protein expression was studied in the human prostate cancer cell line 1542CP3TX. IFN{gamma} increased both the number and abundance of proteins in membrane fractions. In contrast, the expression of annexin 2 and its binding partner p11 decreased by 4-fold after 24 h of exposure, with the remaining anx2t complexes localized to lipid rafts. Within the same time scale, IFN{gamma} reduced the abundance of the peripherally attached, anx2t-associated proteases procathepsin B and plasminogen. The invasive capacity of the cancer cells was reduced by treatment with IFN{gamma} or antibody to annexin 2 in 1542CP3TX cells, but not in LNCaP, an annexin 2-negative prostate cancer cell line. Expression of annexin 2 in LNCaP cells increased their invasiveness. IFN{gamma} induced calpain expression and activation and increased the phosphorylation and degradation of the calpain substrate ABCA1 in 1542CP3TX cancer cells. Surface expression of annexin 2 was reduced in cells treated with glyburide, an ABCA1 inhibitor, whereas inhibition of calpain abrogated IFN{gamma}-induced annexin 2 down-regulation and suppression of Matrigel invasion. The findings suggest annexin 2 externalization is coupled to lipid efflux in prostate epithelium and that IFN{gamma} induces down-regulation of the protease-binding anx2t scaffold at the cell surface and consequently acts to suppress invasiveness through calpain-mediated degradation of the lipid transporter ABCA1.


Received for publication, January 9, 2008 , and in revised form, January 18, 2008.

* This work was supported by the Ludwig Institute for Cancer Research, UCL Branch, London, and by National Cancer Research Institute Grant G0100116 and National Institutes of Health Grant RO1 AG14960. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Formula The on-line version of this article (available at http://www.jbc.org) contains supplemental Figs. 1-5.

1 To whom correspondence should be addressed: Klinisk Immunologisk Afdeling, Aalborg Sygehus Nord, 9100 Aalborg, Denmark. E-mail: sonh{at}rn.dk.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2008 by the American Society for Biochemistry and Molecular Biology.